Amanda M. Nash

Amanda M. Nash

Auto-generated profile, based on publicly available information

Amanda M. Nash

Department of Bioengineering, Rice University, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Science Advances
Verified
Journal Article
Open access
ANAmanda M. Nash
Amanda M. Nash
MJMaria I. Jarvis
Maria I. Jarvis
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
Sudip MukherjeeSudip Mukherjee
Sudip Mukherjee
AHAndrea Hernandez
Andrea Hernandez
OVOmid Veiseh
Omid Veiseh
Proinflammatory cytokines have been approved by the Food and Drug Administration for the treatment of metastatic melanoma and renal carcinoma. However, effective cytokine therapy requires high-dose infusions that can result in antidrug antibodies and/or systemic side effects that limit long-term benefits. To overcome these limitations, we developed a clinically translatable cytokine delivery platform composed of polymer-encapsulated human ARPE-19 (RPE) cells that produce natural cytokines. Tumor-adjacent administration of these capsules demonstrated predictable dose modulation with spatial and temporal control and enabled peritoneal cancer immunotherapy without systemic toxicities. Interleukin-2 (IL2)–producing cytokine factory treatment eradicated peritoneal tumors in ovarian and colorectal mouse models. Furthermore, computational pharmacokinetic modeling predicts clinical translatability to humans. Notably, this platform elicited T cell responses in NHPs, consistent with reported biomarkers of treatment efficacy without toxicity. Combined, our findings demonstrate the safety and efficacy of IL2 cytokine factories in preclinical animal models and provide rationale for future clinical testing in humans.

26 June 2021 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
ANAmanda Nash
Amanda Nash
BKBoram Kim
Boram Kim
RKRobert Krencik
Robert Krencik
OVOmid Veiseh
Omid Veiseh

12 September 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ANAmanda M. Nash
Amanda M. Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
BCBertha Castillio
Bertha Castillio
AHAndrea Hernandez
Andrea Hernandez
APAarthi Pugazenthi
Aarthi Pugazenthi
OVOmid Veiseh
Omid Veiseh
Purpose: IL2 immunotherapy has the potential to elicit immune-mediated tumor lysis via activation of effector immune cells, but clinical utility is limited due to pharmacokinetic challenges as well as vascular leak syndrome and other life-threatening toxicities experienced by patients. We developed a safe and clinically translatable localized IL2 delivery system to boost the potency of therapy while minimizing systemic cytokine exposure. Experimental Design: We evaluated the therapeutic efficacy of IL2 cytokine factories in a mouse model of malignant mesothelioma. Changes in immune populations were analyzed using time-of-flight mass cytometry (CyTOF), and the safety and translatability of the platform were evaluated using complete blood counts and serum chemistry analysis. Results: IL2 cytokine factories enabled 150× higher IL2 concentrations in the local compartment with limited leakage into the systemic circulation. AB1 tumor burden was reduced by 80% after 1 week of monotherapy treatment, and 7 of 7 of animals exhibited tumor eradication without recurrence when IL2 cytokine factories were combined with anti–programmed cell death protein 1 (aPD1). Furthermore, CyTOF analysis showed an increase in CD69+CD44+ and CD69−CD44+CD62L− T cells, reduction of CD86−PD-L1− M2-like macrophages, and a corresponding increase in CD86+PD-L1+ M1-like macrophages and MHC-II+ dendritic cells after treatment. Finally, blood chemistry ranges in rodents demonstrated the safety of cytokine factory treatment and reinforced its potential for clinical use. Conclusions: IL2 cytokine factories led to the eradication of aggressive mouse malignant mesothelioma tumors and protection from tumor recurrence, and increased the therapeutic efficacy of aPD1 checkpoint therapy. This study provides support for the clinical evaluation of this IL2-based delivery system. See related commentary by Palanki et al., p. 5010

12 June 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
HCHelen D. Clark
Helen D. Clark
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
JSJake Schladenhauffen
Jake Schladenhauffen
JDJonathon Debonis
Jonathon Debonis
JAJuan Carlos Amador-Molina
Juan Carlos Amador-Molina
SWShannon N. Westin
Shannon N. Westin
Purpose: Platinum-resistant high-grade serous ovarian carcinomas (HGSOC) are associated with poor therapeutic outcomes. Although HGSOC frequently metastasizes to the intraperitoneal (IP) cavity, the success of IP cytokine therapies, such as IL2, has been hampered by local toxicity and administration difficulties. AVB-001 is a novel IL2 delivery system consisting of encapsulated, allogeneic cells engineered for constitutive human IL2 (hIL2) expression. Patients and Methods: This is a phase I dose-escalation trial of AVB-001 for the treatment of HGSOC (NCT05538624). A single dose of AVB-001 was administered by IP laparoscopy, enabling hIL2 doses from 0.6 to 3.6 μg hIL2/kg/day. Safety was evaluated using NCI Common Terminology Criteria for Adverse Events v5.0. Efficacy was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immunotherapy RECIST criteria. Results: The trial enrolled 14 patients across four dose levels. Three (21.4%) patients experienced grade 3 treatment-related adverse events (TRAE); no grade 4 to 5 TRAEs were reported. There was one dose-limiting toxicity. There was one unconfirmed partial response but no confirmed responses (overall response rate 0%). Stable disease was observed in seven patients, with a median duration of 2.57 months (range, 2.03–4.23). The clinical benefit rate was 14.3% (n = 2). Pharmacokinetics demonstrated dose-dependent increases in serum IL2, peaking at 1 day after implantation. Immunologic analyses revealed sustained CD8+ and CD4+ T-cell proliferation without corresponding proliferation in regulatory T cells. Dose-dependent CTLA-4 receptor upregulation was observed on CD8+ and CD4+ T cells, whereas PD-1 and TIM-3 remained unchanged. Conclusions: In patients with HGSOC, AVB-001 is safe and effectively activates cytotoxic T cells, supporting further investigation of this locoregional immunotherapy.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
ANAmanda Nash
Amanda Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
BCBertha Castillo
Bertha Castillo
ANAnnie Nguyen
Annie Nguyen
ACAndrew Cui
Andrew Cui
OVOmid Veiseh
Omid Veiseh
Pancreatic cancer is often diagnosed at advanced stages and responds poorly to chemotherapy. Because high tumor T cell infiltration corresponds with better clinical outcomes in pancreatic cancer patients, immunotherapy has gained significant interest over the last decade for the treatment of recurrent pancreatic cancer. IL-12 is a proinflammatory cytokine with pleiotropic effects including activation of CD8+ T cells and NK cells. Unfortunately, systemic high dose IL-12 administration led to severe toxicities in clinical trials which has limited further development of this cytokine as a cancer therapeutic. To address this limitation, we developed an implantable cytokine delivery platform to allow for local administration of IL-12. These cytokine factories, composed of genetically engineered epithelial cells encapsulated in biocompatible polymers, allow for safe and controlled dosing in vivo. Tumor adjacent administration of IL-12-based cytokine factories caused reduction of intraperitoneal pan02 tumor burden by 80% after only 1 week of treatment in mice with pancreatic cancer. Single cell RNAseq of the tumor adjacent immune cells at this time point showed 2x more T and NK cells present in the IL-12 treated mice than untreated mice suggesting modulation of the tumor microenvironment via immune cell infiltration. Importantly, the necessary IL-12 dose was well tolerated in all mice without signs of toxicity for 180 days. In efforts to evaluate the translatability of this platform, we further tested IL-12-based cytokine factories in a non-human primate. The cytokine factories produced a high local IL-12 concentration without substantial leakage into the systemic circulation and were well tolerated by the primates as shown by the lack of fever or weight loss, as well as the lack of renal or liver toxicity. Our findings highlight the therapeutic potential of IL-12 treatments when administered locally via cytokine factories in preclinical animal models. Further, these findings provide rationale for future development and clinical testing of cytokine factories for treatment of a wide range of metastatic peritoneal cancers in humans. Citation Format: Amanda Nash, Samira Aghlara-Fotovat, Bertha Castillo, Annie Nguyen, Andrew Cui, Andrea Hernandez, Peter Rios, Sofia Ghani, Ira Joshi, Chunyu Xu, Rahul Sheth, Weiyi Peng, Jose Oberholzer, Amir Jazaeri, Omid Veiseh. IL-12-based cytokine factories modulate tumor microenvironment to eradicate pancreatic tumors in mice and are well tolerated in non-human primates [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3547.

7 November 2022 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
ANAmanda Nash
Amanda Nash
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
AHAndrea Hernandez
Andrea Hernandez
SGSofia Ghani
Sofia Ghani
IJIra Joshi
Ira Joshi
OVOmid Veiseh
Omid Veiseh
Background Pancreatic cancer is often diagnosed at advanced stages and responds poorly to chemotherapy.1 Because high tumor T cell infiltration corresponds with better clinical outcomes in pancreatic cancer patients, immunotherapy has gained significant interest for treatment. IL-12 is a proinflammatory cytokine that activates CD8+ T cells and NK cells.2 Unfortunately, systemic high dose IL-12 administration led to severe toxicities in clinical trials which limited further development of this cytokine as a cancer therapeutic. To address this limitation, we developed an implantable cytokine delivery platform for local administration of IL-12. These cytokine factories, composed of genetically engineered cells encapsulated in biocompatible polymers, allow for safe and controlled dosing in vivo. Cytokine PK Studies Supernatant from individual capsules were assayed at 1-, 2-, 4-, or 24-hours using ELISA (n=6). Mouse Studies For IP tumors, 1e6 pan02 cells were injected in the IP space of mice. Cytokine factories were implanted 7 days post tumor injection. Primate Studies Cytokine factories were administered to cynomolgus macaques (n=1). Complete blood count and blood chemistry analysis were performed for 28 days after administration. IVIS Imaging Mice were injected in the IP space with D-luciferin (300 µg/mL, PerkinElmer). Photographs and luminescent images were acquired 10 minutes after injection. Results Local administration of IL-12-based cytokine factories caused reduction of pan02 tumor burden by 80% after 1 week of treatment in mice (figure 1). Single cell RNAseq of the tumor adjacent immune cells showed 2x more T cells in IL-12 treated mice than untreated mice suggesting immune cell infiltration. Importantly, the IL-12 dose was well tolerated in all mice for 180 days. In efforts to evaluate the translatability of this platform, we further tested IL-12-based cytokine factories in a non-human primate. The cytokine factories produced a high local IL-12 concentration without substantial leakage into the systemic circulation and were well tolerated by the primates as shown by the lack of fever or weight loss, as well as the lack of renal or liver toxicity. Conclusions Our findings highlight the therapeutic potential of IL-12 treatments when administered locally via cytokine factories in preclinical animal models. Further, these findings provide rationale for future clinical testing of cytokine factories in a wide range of metastatic cancers in humans. References Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, Mahmoud MM, Warsi MK, Rasool M, Jamal M.S, Prospects of IL-2 in Cancer Immunotherapy. Biomed Res Int 2018;2018: 9056173. McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response. Semin Oncol 2006;33:583–587. IL-12 cytokine factories reduce mice pancreatic tumor burden a) Total flux calculated from IVIS imaging prior to treatment with RPE-mIL2, RPE-mIL12, RPE only, or untreated (n=5). b) Representative IVIS images of each treatment group 5 days post treatment.